With expected sales for GLP1Rs in obesity estimated to surpass $126 billion by 2030, this drug category presents a lucrative ...
A new Biden administration proposal could allow millions of Americans with obesity to access weight-loss drugs like Wegovy ...
The Biden administration believes that including obesity drugs in Medicare coverage will reduce out-of-pocket costs for the ...
Mounjaro is a treatment for Type 2 diabetes that activates GIP and GLP-1 pathways to help regulate blood sugar. It’s part of ...
Eli Lilly topped the list of the 20 biggest pharmas by market cap with a more than 39% improvement year-to-date in its share ...
Discover the best Black Friday deals, Fort Wayne's ranking as a top retirement spot, and Walmart's pullback on diversity policies.
4h
The stocks of companies that make the new class of drugs to treat obesity and manage diabetes were higher across the board ...
The Biden administration plans to require Medicare and Medicaid to offer coverage of weight loss medications for people seeking obesity treatment.The new rule, which was proposed by the administration ...
The White House said it's moving to make the federal health insurance plans pay for anti-obesity drugs such as Novo Nordisk's Wegovy and Eli Lilly's Zepbound for people who are obese, even if they don ...
The Biden administration proposed a rule to let Medicare and Medicaid cover obesity drugs like Ozempic. Millions would ...
In clinical trials, most participants taking Wegovy or Mounjaro to treat obesity lost an average of 15% to 22% of their body ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback